SAN DIEGO, Dec. 4 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that data from its Phase 2 and Phase 3 clinical trials of FavId(R) following Rituxan(R) induction therapy in patients with follicular B-cell non-Hodgkin's lymphoma (NHL) will be reported at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO )
Long-term follow-up data from Favrille's Phase 2 clinical trial will be presented by co-primary investigator Jane N. Winter, M.D., Feinberg School of Medicine at Northwestern University, during an oral presentation at 3:30 p.m. Eastern Time on Monday, December 11, 2006, at the Orange County Convention Center. In addition, progress from the Company's Phase 3 clinical trial will be reported during a poster session beginning at 9:00 a.m. Eastern Time on Sunday, December 10, 2006.
Favrille will also host a post-ASH data briefing at the InterContinental hotel in New York City at 4:30 p.m. Eastern Time on Wednesday, December 13, 2006, to discuss the implications of the data for the Company's ongoing Phase 3 clinical trial and the analysis of the primary endpoint, time to disease progression, which is expected during the second half of 2007. Favrille's management team will be joined by Paul Hamlin, M.D., Memorial Sloan-Kettering Cancer Center in New York, and John Timmerman, M.D., Division of Hematology and Oncology at the University of California, Los Angeles. To RSVP for Favrille's post-ASH data briefing, please contact Kim Richards at (619) 849-5377 or krichards@pnlifesciences.com. A live webcast of the event can be accessed at www.favrille.com. A replay will be available approximately one hour after the presentation and archived until January 13, 2007.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.CONTACT: Tamara A. Seymour, CFO and Vice President, Finance &Administration, +1-858-526-8035, tseymour@favrille.com, or Pete De Spain,Associate Director, Investor Relations & Corporate Communications,+1-858-526-2426, pdespain@favrille.com, both of Favrille, Inc.
Web site: http://www.favrille.com/
